Bayer AG is preparing a $10.5 billion push to resolve ongoing and future litigation tied to its Roundup herbicide. The proposed framework includes $7.5 billion for a Missouri-based state court class-action settlement intended to cover both filed claims and potential claims over a 20-year period, along with $3 billion earmarked to settle existing U.S. lawsuits brought by former users alleging non-Hodgkin lymphoma linked to glyphosate exposure.
The litigation stems from Bayer's $66 billion acquisition of Monsanto, which transferred thousands of product liability claims to the German conglomerate. Despite paying more than $10 billion in prior verdicts and settlements, Bayer still faces approximately 67,000 pending claims. Plaintiffs allege that long-term exposure to glyphosate caused cancer, while Bayer maintains that the product is safe and cites federal regulatory findings that glyphosate is not carcinogenic.
The company's renewed settlement effort follows the decision by the Supreme Court of the United States to review a $1.25 million Missouri jury verdict against Monsanto. That appeal centers on whether certain state-law failure-to-warn claims are preempted by federal law, an issue that could shape liability exposure across thousands of similar cases.
For insurance claims adjusters, the proposed settlement signals several key implications:
Long-tail exposure management: A 20-year class structure attempts to cap future liabilities, offering insight into how mass tort defendants may seek predictability in reserving strategies.
Preemption defenses: The Supreme Court review may influence how carriers evaluate federal preemption arguments in product liability and toxic tort cases.
Aggregation risk: With tens of thousands of claims still active, insurers and reinsurers face ongoing aggregation challenges, particularly for legacy general liability policies.
Settlement valuation trends: The scale of this proposed resolution provides a benchmark for future mass tort negotiations involving agricultural chemicals and alleged carcinogens.
The outcome will be closely watched across the insurance industry, especially among carriers handling product liability, excess, and reinsurance placements tied to chemical exposure risks.
